The main goal of the STEATO-FH study is to determine the prevalence of liver steatosis within the Heterozygous Familial Hypercholesterolemia patient population.
Patient aged 35 or over
Consultation at Nantes, Rennes or Angers University Hospital during the inclusion period
With a diagnosis of familial hypercholesterolemia defined by the presence of a genetic variant, ACMG classes 4 & 5 on LDLR, APOB or PCSK9
Patient not objecting to inclusion in study (no written objection)
Protected patients: minors, adults under guardianship, curatorship and/or safeguard of justice
Pregnant or breast-feeding
Active viral hepatitis
Hemochromatosis
Nantes University Hospital
Lead sponsor
University Hospital, Angers
Collaborator
Rennes University Hospital
Collaborator